Moderna has received Health Canada's approval for its respiratory syncytial virus messenger ribonucleic acid (mRNA) vaccine ...
Moderna (NASDAQ: MRNA) Q3 2024 Earnings Call Nov 07, 2024, 8:00 a.m. ET Good day, and thank you for standing by. Welcome to ...
According to UNICEF's State of the World's Children 2023 report, in Latin America and the Caribbean, 6.8 million children did ...
Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...
They found that mRNA vaccines that target C. diff cells and the toxins they produce generated a lasting immune response in ...
Hosted on MSN4h
Novavax to Report Q3 Earnings: Here's What to ExpectNovavax NVAX is scheduled to report third-quarter 2024 earnings on Nov. 12, before the opening bell. In the last reported ...
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read More on MRNA: Moderna NewsMORE ...
Our press release and the slides accompanying today's call are posted on our website and available at ... consisting of 26 grams of mRNA material for a preclinical cell and gene therapy customer. This ...
Moderna President Stephen Hoge, M.D., has taken on an expanded role, adding new responsibilities overseeing Moderna’s commercial organization. As President, Dr. Hoge will now be responsible for ...
Health Canada approves Moderna’s RSV vaccine, mRESVIA for adults aged 60 years and older: Cambridge, Massachusetts Monday, November 11, 2024, 12:00 Hrs [IST] Moderna, Inc., a le ...
US mRNA specialist Moderna today announced Health Canada has approved mRESVIA (respiratory syncytial virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback